Research programme: antifungals - Cytokinetics
Latest Information Update: 16 Mar 2009
At a glance
- Originator Cytokinetics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 16 Mar 2009 Discontinued - Preclinical for Mycoses in USA (unspecified route)
- 08 Mar 2004 This programme is available for licensing worldwide (http://cytokinetics.com)
- 14 Jun 2002 Preclinical trials in Mycoses in USA (unspecified route)